Aprinoia Therapeutics (Aprinoia Therapeutics) Price-to-Tangible-Book : (As of May. 01, 2024)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Price-to-Tangible-Book?

As of today (2024-05-01), Aprinoia Therapeutics's share price is $0.00. Aprinoia Therapeutics's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was $-2.94. Hence, Aprinoia Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Aprinoia Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

APRI's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.69
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Aprinoia Therapeutics's share price is $0.00. Aprinoia Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2023 was $-2.94. Hence, Aprinoia Therapeutics's P/B Ratio of today is .

Aprinoia Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Aprinoia Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Price-to-Tangible-Book Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Price-to-Tangible-Book

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Price-to-Tangible-Book	-	-	-	-

Competitive Comparison of Aprinoia Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Aprinoia Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Price-to-Tangible-Book falls into.

Aprinoia Therapeutics Price-to-Tangible-Book Calculation

Aprinoia Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	0.00	/	-2.944
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Aprinoia Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines